Advertisement

Picture ConsulTech GmbH GDPR-compliant E-Col Cloud Document Management 650x80px
Document › Details

Coulter Partners. (2/26/20). "Press Release: Coulter Partners Secures Chief Scientific Officer for Centogene".

Region Region Cambridge, MA
  Country United States (USA)
Organisations Organisation Coulter Partners (The Coulter Partnership Ltd.)
  Organisation 2 Centogene US, LLC
  Group Centogene (Group)
Product Product  CentoMD® rare disease variant database
Index term Index term Centogene–Coulter Partners: recruitment services, 202002 supply service placement of Philip Lambert as CSO at Centogen based in US
Persons Person Lambert, Philip (Centogene 202002– CSO located in Cambrigde MA before Life Biosciences + Charles River + VivoPath)
  Person 2 Osterholz, Daniela (Centogene 202002 Head of Human Resources)
     


Coulter Partners was very pleased to partner recently with CENTOGENE (Nasdaq: CNTG) to secure the appointment of Philip Lambert, PhD in Cambridge, MA as Chief Scientific Officer. With more than two decades of experience in the global drug discovery and pre-clinical development sectors, Philip will have the overall responsibility of driving scientific programs to align with the needs of pharmaceutical partners.

Daniela Osterholz, Head of Human Resources at CENTOGENE, commented: “We are extremely pleased to have Philip Lambert join CENTOGENE’s Executive Leadership Team, and the extensive experience and knowledge in the rare disease field he adds to the Company. Philip’s appointment and the further profiling of the leadership team marks a significant advancement to the Company’s pursuit to shorten the diagnostic odyssey and create treatment solutions for patients and their families. I would like to thank the team at Coulter Partners for their outstanding professional support in achieving this high caliber appointment.”

Philip joins CENTOGENE from Life Biosciences, a global company focused on extending the healthy lifespan of individuals by investigating eight biological pathways believed to increase longevity. He served as Senior Vice President of Discovery and Labs as well as Chief Operating Officer of two subsidiary companies, Selphagy Therapeutics and Spotlight Biosciences. Prior to Life Biosciences, Philip served as Scientific Partner and Head of Discovery at Charles River Laboratories, where he was responsible for establishing scientific credibility and delivering the business to client companies and venture capital firms. Philip also co-founded VivoPath, a preclinical screening company, offering clients discovery and development services for proof-of-concept testing. He holds a PhD in Neuropharmacology from Imperial College – University of London and a BSc in Pharmacology from the University of Liverpool.


About CENTOGENE

CENTOGENE is a commercial-stage company focused on rare diseases that transforms real-world clinical and genetic data into actionable information for patients, physicians and pharmaceutical companies. The Company’s goal is to bring rationality to treatment decisions and to accelerate the development of new orphan drugs by using our knowledge of the global rare disease market, including epidemiological and clinical data and innovative biomarkers. CENTOGENE has developed a global proprietary rare disease platform based on our real-world data repository with approximately 2.1 billion weighted data points from approximately 465,000 patients representing over 120 different countries as of September 30, 2019, or an average of over 500 data points per patient.

The Company’s platform includes epidemiologic, phenotypic, and genetic data that reflects a global population, and also a biobank of these patients’ blood samples. CENTOGENE believes this represents the only platform that comprehensively analyzes multi-level data to improve the understanding of rare hereditary diseases, which can aid in the identification of patients and improve our pharmaceutical partners’ ability to bring orphan drugs to the market. As of September 30, 2019, the Company collaborated with over 35 pharmaceutical partners for over 30 different rare diseases. For more information please visit https://www.centogene.com/


KEY PLAYERS [at Coulter Partners]

Dr Kay Wardle (BSc PhD MA MCIPD)
Managing Partner

Bianca Coulter
CEO

Mark Sharp
Director

Emily Richardson
Research Associate

Dr Pat Mileham (BSc PhD DIC)
Senior Production Associate

Laoise McGovern
Senior Project Co-ordinator

   
Record changed: 2020-03-02

Advertisement

Picture [iito] Männer Ballett 650x80px

More documents for Coulter Partners (The Coulter Partnership Ltd.)


To subscribe to our free, monthly newsletter for the European life sciences, please send an e-mail to info@iito.de and simply fill the subject line with the word »LSE Newsletter«

To get even more information, please take a look at our [gs] professional services offering and read the gene-sensor Product Flyer [PDF file]

Advertisement

Picture ConsulTech GmbH Berlin Grant Application and Coordination 650x80px




» top